Skip to main content

Table 3 Risk of severe asthma exacerbation by different classes of antipsychotics and doses after excluding schizophrenia patients

From: Typical antipsychotics is associated with increased risk of severe exacerbation in asthma patients: a nationwide population-based cohort study

Characteristics No. (%) Conditional logistic regression P for trend
Case period Control period Crude OR
(95% CI)
P value Adjusted ORa
(95% CI)
P value
No use of antipsychotics 17,900 (96.73) 18,008 (97.31) Ref   Ref   
Any use of antipsychotics 606 (3.3) 498 (2.7) 1.49 (1.26–1.77) < 0.001 1.28 (1.06–1.57) 0.011  
Antipsychotics classb        
 Typical only 260 (1.40) 186 (1.01) 1.62 (1.29–2.03) < 0.001 1.37 (1.07–1.76) 0.012  
 Atypical only 326 (1.76) 298 (1.61) 1.32 (1.01–1.71) 0.039 1.15 (0.86–1.54) 0.344  
 Both 20 (0.11) 14 (0.08) 1.87 (0.81–4.30) 0.142 1.60 (0.66–3.92) 0.300  
Dose        
 Low (≤ 0.25 DDD) 535 (2.89) 441 (2.38) 1.48 (1.25–1.76) < 0.001 1.27 (1.05–1.54) 0.016 0.005
 Medium to high (> 0.25 DDD) 71 (0.38) 57 (0.31) 1.81 (1.17–2.78) 0.007 1.65 (1.03–2.62) 0.036  
Dose (typical only)        
 Low (≤ 0.25 DDD) 249 (1.35) 181 (0.98) 1.60 (1.27–2.01) < 0.001 1.37 (1.06–1.76) 0.015 0.004
 Medium to high (> 0.25 DDD) 11 (0.06) 5 (0.03) 4.30 (1.15–16.15) 0.031 5.74 (1.33–24.67) 0.019  
Dose (atypical only)        
 Low (≤ 0.25 DDD) 271 (1.46) 252 (1.36) 1.30 (0.99–1.70) 0.057 1.12 (0.83–1.52) 0.451 0.282
 Medium to high (> 0.25 DDD) 55 (0.30) 46 (0.25) 1.51 (0.92–2.47) 0.107 1.33 (0.78–2.27) 0.301  
  1. DDD: defined daily dose, OR: odds ratio
  2. aAdjusted for heart failure, ischemic heart disease, stroke, gastroesophageal reflux disease, obesity disorder, rhinosinusitis, schizophrenia, depression, bipolar disorder, pneumonia, acute upper airway infection, antiplatelet agents, cardioselective β-blocker, non-selective β-blocker, NSAID, anti-psychotics, anti-depressants, bladder anticholinergic agents, gastrointestinal tract anticholinergic agents, first generation anti-histamine, second/third generation anti-histamine, short-acting beta-agonist, short-acting muscarinic antagonist, short-acting beta-agonist plus short-acting muscarinic antagonist, long-acting beta-agonist plus long-acting beta-agonist, long-acting beta-agonist, xanthine inhibitor, leukotriene receptor antagonist
  3. bSee Additional file 1: Table S1